Britain’s National Audit Office has opened preliminary enquiries into the cost of the UK–United States drug pricing agreement after six parliamentary committee chairs warned that taxpayers may be funding a multi-billion-pound commitment without adequate scrutiny.
What Davies told MPs
NAO Comptroller and Auditor General Gareth Davies wrote to the chairs on Tuesday saying he recognised “significant parliamentary interest” in the arrangement struck with the Trump administration. He instructed his team to make initial enquiries and promised a follow-up once that work is complete.
The letter followed a joint request last month from committees covering health, public accounts and international trade. Lawmakers asked whether the deal, which doubles UK spending on innovative medicines as a share of GDP by 2035, represents value for money.
Terms of the pact
Under the agreement announced earlier this year, the UK pledged to raise pharmaceutical investment from 0.3 per cent of GDP to 0.6 per cent by 2035 in exchange for three years of tariff-free access to the U.S. market for selected goods. Ministers have said the package will cost about £1 billion over the current spending review period, with no extra funding earmarked in this autumn’s budget.
Officials have refused to publish detailed modelling, arguing disclosure could harm international relations and commercial confidentiality. That secrecy has fuelled opposition claims that Downing Street bought short-term trade relief at the expense of the National Health Service medicines budget.
Why watchdog involvement matters
While the NAO cannot block treaties, its reports often reshape how departments account for long-term liabilities. Health economists said even preliminary enquiries could force the Department of Health and Social Care to document assumptions about future drug prices, uptake of new therapies and any pass-through to NHS prescribing budgets.
Trade department officials maintain the deal will attract research investment to Britain and give patients faster access to cutting-edge treatments. Critics counter that tying NHS spending to a GDP ratio could lock in higher prices regardless of clinical need.
Parliamentary calendar
Committee chairs are expected to summon ministers once Davies confirms the scope of a fuller study. Opposition health spokespeople have already demanded a Commons statement before any secondary legislation implementing payment triggers.
Prime Minister Andy Burnham’s government is simultaneously negotiating closer EU economic ties, a balancing act that makes transparency on U.S. side letters politically sensitive. Business Secretary Jonathan Reynolds has argued Britain must diversify partners, but he has not released the underlying cost-benefit tables.
Industry reaction
Pharmaceutical lobby groups welcomed the audit as a chance to demonstrate return on investment, while patient charities asked the NAO to examine whether rural hospitals would bear disproportionate costs. Generic manufacturers fear the pact could extend patent protections that keep cheaper copies off the market.
What happens next
Davies said his team would revert to committee chairs after preliminary enquiries, a process that typically takes several weeks. If he launches a formal value-for-money investigation, departments would be required to supply contracts, forecasts and correspondence with the White House.
Until then, NHS planners must budget as if the GDP ratio target is binding, even as MPs wait to see whether the spending watchdog concludes that ministers sold Parliament a deal whose true price remains hidden.